DONANEMAB AND THE FUTURE OF ALZHEIMER’S TREATMENT: BETWEEN INNOVATION AND CAUTION
DOI:
https://doi.org/10.31435/ijitss.4(48).2025.4214Keywords:
Alzheimer Disease, Amyloid β-Peptides, Donanemab, Adverse Drug Reactions, Efficacy StudiesAbstract
Introduction and Objective: Alzheimer’s disease (AD) is the leading cause of dementia, mainly affecting people over 65. Its growing prevalence, driven by population aging, highlights the need for disease-modifying therapies. This article reviews donanemab - a monoclonal antibody targeting β-amyloid plaques - with emphasis on efficacy, safety, and regulatory landscape.
State of Knowledge: Donanemab may slow cognitive decline in early AD, especially in patients with low-to-intermediate tau levels. Clinical trials showed a 35% reduction in disease progression. However, the treatment is associated with amyloid-related imaging abnormalities (ARIA), particularly in APOE ε4 carriers.
Conclusions: Donanemab offers meaningful clinical benefits in early AD, but safety concerns and inconsistent regulatory decisions complicate its implementation. Though approved in the U.S., Japan, and China, it was denied EMA authorization due to ARIA risks. In Poland, access is limited to individual cases via the Named Patient Import Scheme. Its future use will require precise patient selection and continued safety monitoring. The case of donanemab illustrates the broader tension between therapeutic innovation and patient protection.
References
2023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023 Apr;19(4):1598-1695. doi: 10.1002/alz.13016. Epub 2023 Mar 14. PMID: 36918389.
Lopatko Lindman K, Weidung B, Olsson J, Josefsson M, Kok E, Johansson A, Eriksson S, Hallmans G, Elgh F, Lövheim H. A genetic signature including apolipoprotein Eε4 potentiates the risk of herpes simplex-associated Alzheimer's disease. Alzheimers Dement (N Y). 2019 Nov 4;5:697-704. doi: 10.1016/j.trci.2019.09.014. PMID: 31921962; PMCID: PMC6944738.
Zheng Q, Wang X. Alzheimer's disease: insights into pathology, molecular mechanisms, and therapy. Protein Cell. 2025 Feb 1;16(2):83-120. doi: 10.1093/procel/pwae026. PMID: 38733347; PMCID: PMC11786724.
Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, Cummings J, van der Flier WM. Alzheimer's disease. Lancet. 2021 Apr 24;397(10284):1577-1590. doi: 10.1016/S0140-6736(20)32205-4. Epub 2021 Mar 2. PMID: 33667416; PMCID: PMC8354300.
World Social Report 2023: Leaving No One Behind In An Ageing World
United Nations Department of Economic and Social Affairs, Population Division (2020). World Population Ageing 2020 Highlights: Living arrangements of older persons (ST/ESA/SER.A/451).
A. Sharma, S. Rudrawar, S. B. Bharate i H. R. Jadhav, RSC Med. Chem., 2025, 16, 652–693, DOI: 10.1039/D4MD00630E.
Gillette-Guyonnet S, Andrieu S, Nourhashemi F, Gardette V, Coley N, Cantet C, Gauthier S, Ousset PJ, Vellas B; REAL.FR study group. Long-term progression of Alzheimer's disease in patients under antidementia drugs. Alzheimers Dement. 2011 Nov;7(6):579-92. doi: 10.1016/j.jalz.2011.02.009. PMID: 22055975.
Chermont dos Santos Moreira N, de Freitas Lima JE, Marchiori MF, Carvalho I, Sakamoto-Hojo ET. Neuroprotective effects of cholinesterase inhibitors: Current scenario in therapies for Alzheimer's disease and future perspectives. Ageing Res Rev. 2022;70:101397. doi:10.1016/j.arr.2022.101397.
Fan F, Liu H, Shi X, Ai Y, Liu Q, Cheng Y. The efficacy and safety of Alzheimer's disease therapies: An updated umbrella review. J Alzheimers Dis. 2022;85(2):553-564. doi:10.3233/JAD-215423.
Soheili M, Karimian M, Hamidi G, Salami M. NMDA receptor antagonists: Repositioning of memantine as a multitargeting agent for Alzheimer's therapy. Iran J Basic Med Sci. 2021;24(2):123-135. doi:10.22038/IJBMS.2020.50536.11512.
Qi X, Nizamutdinov D, Yi SS, Wu E, Huang JH. Disease Modifying Monoclonal Antibodies and Symptomatic Pharmacological Treatment for Alzheimer's Disease. Biomedicines. 2024 Nov 19;12(11):2636. doi: 10.3390/biomedicines12112636. PMID: 39595200; PMCID: PMC11592475.
Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512–527. doi:10.1001/jama.2023.13239
Jawhar S, Wirths O, Bayer TA. Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease. J Biol Chem. 2011 Nov 11;286(45):38825-32. doi: 10.1074/jbc.R111.288308. Epub 2011 Sep 29. PMID: 21965666; PMCID: PMC3234707.
Bayer TA. Pyroglutamate Aβ cascade as drug target in Alzheimer's disease. Mol Psychiatry. 2022 Apr;27(4):1880-1885. doi: 10.1038/s41380-021-01409-2. Epub 2021 Dec 8. PMID: 34880449; PMCID: PMC9126800.
Uhlmann RE, Rother C, Rasmussen J, Schelle J, Bergmann C, Ullrich Gavilanes EM, Fritschi SK, Buehler A, Baumann F, Skodras A, Al-Shaana R, Beschorner N, Ye L, Kaeser SA, Obermüller U, Christensen S, Kartberg F, Stavenhagen JB, Rahfeld JU, Cynis H, Qian F, Weinreb PH, Bussiere T, Walker LC, Staufenbiel M, Jucker M. Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life. Nat Neurosci. 2020 Dec;23(12):1580-1588. doi: 10.1038/s41593-020-00737-w. Epub 2020 Nov 16. PMID: 33199898; PMCID: PMC7783656.
Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, Apostolova LG, Salloway SP, Skovronsky DM. Donanemab in Early Alzheimer's Disease. N Engl J Med. 2021 May 6;384(18):1691-1704. doi: 10.1056/NEJMoa2100708. Epub 2021 Mar 13. PMID: 33720637.
Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S, Collins EC, Sims JR, Mintun MA. Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial. JAMA Neurol. 2022 Dec 1;79(12):1250-1259. doi: 10.1001/jamaneurol.2022.3392. PMID: 36251300; PMCID: PMC9577883
Manly JJ, Deters KD. Donanemab for Alzheimer Disease-Who Benefits and Who Is Harmed? JAMA. 2023 Aug 8;330(6):510-511. doi: 10.1001/jama.2023.11704. PMID: 37459138.
Roytman M, Mashriqi F, Al-Tawil K, Schulz PE, Zaharchuk G, Benzinger TLS, Franceschi AM. Amyloid-Related Imaging Abnormalities: An Update. AJR Am J Roentgenol. 2023 Apr;220(4):562-574. doi: 10.2214/AJR.22.28461. Epub 2022 Nov 2. PMID: 36321981.
Greenberg SM, Bax F, van Veluw SJ. Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms. Nat Rev Neurol. 2025 Apr;21(4):193-203. doi: 10.1038/s41582-024-01053-8. Epub 2025 Jan 10. PMID: 39794509.
Cogswell PM, Barakos JA, Barkhof F, Benzinger TS, Jack CR Jr, Poussaint TY, Raji CA, Ramanan VK, Whitlow CT. Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice. AJNR Am J Neuroradiol. 2022 Sep;43(9):E19-E35. doi: 10.3174/ajnr.A7586. Epub 2022 Aug 11. PMID: 35953274; PMCID: PMC9451628.
Sima DM, Phan TV, Van Eyndhoven S, Vercruyssen S, Magalhães R, Liseune A, Brys A, Frenyo P, Terzopoulos V, Maes C, Guo J, Hughes R, Gabr RE, Huijbers W, Saha-Chaudhuri P, Curiale GG, Becker A, Belachew S, Van Hecke W, Ribbens A, Smeets D. Artificial Intelligence Assistive Software Tool for Automated Detection and Quantification of Amyloid-Related Imaging Abnormalities. JAMA Netw Open. 2024 Feb 5;7(2):e2355800. doi: 10.1001/jamanetworkopen.2023.55800. PMID: 38345816; PMCID: PMC10862143
Teipel SJ, Temp AGM, Lutz MW. Bayesian meta-analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high-dose gantenerumab in prodromal and mild Alzheimer's disease. Alzheimers Dement (N Y). 2024 Feb 22;10(1):e12454. doi: 10.1002/trc2.12454. PMID: 38389855; PMCID: PMC10883242.
De Strooper, Bart et al. The regulatory rollercoaster continues—EMA refuses donanemab; The Lancet, Volume 405, Issue 10492, 1810 - 1812
European Medicines Agency. (2024). EMA decision on donanemab: Public assessment report. Retrieved from www.ema.europa.eu. (access 20.05.2025)
Lilly, E. Donanemab (Kisunla™) approval in the United States, Japan, and China. Retrieved from www.lilly.com. (access 20.05.2025)
Alzheimer's Society responds to MHRA and NICE announcements on donanemab. Retrieved from alzheimers.org.uk. (access 20.05.2025)
Alzheimer Europe. (2024). Alzheimer Europe response to EMA decision on donanemab. Retrieved from www.alzheimereurope.org. (access 20.05.2025)
Import for individual needs - Agency for Health Technology Assessment and Tariff System. Retrieved from atom.gov.pl. (access 20.05.2025)
Downloads
Published
Issue
Section
License
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
